Advanced Therapy Medicinal Product (ATMP)

An advanced therapy medicinal product (ATMP) is a medicinal product based on genes, tissues or cells, offering ground-breaking treatment opportunities.


ATMPs can be classified into three main types :


  • Gene therapy medicinal product
  • Somatic cell therapy medicinal product
  • Tissue engineered medicinal product


Some ATMPs are referred to as “combined ATMPs”: they contain one or more medical devices as an integral part of the medicine.


Authorization Process for Advanced Therapies

All advanced therapies are authorized centrally via the European Medicines Agency (EMA) and benefit from a single evaluation and authorization procedure


The criteria for ATMPs are set out in Article 17 of Regulation (EC) No 1394/2007. EMA’s Committee for Advanced Therapies (CAT) delivers scientific recommendations on ATMP classification after consultation with the European Commission within 60 days after receipt of the request.

Sponsors requiring clarification as to whether their product is classified as an ATMP can receive confirmation from the committee for advanced therapies (CAT) prior to submitting any application to the Agency. This advice is provided free of charge within 60 days of receipt of a valid request from an applicant.


BlueReg can guide you through this complex area to submit a classification application to CAT to determine if your product meets the requirements to be defined as an ATMP. Our team can also support you through the entire application process from development, to registration and post-approval management.


Our experts

Associated Resources

Define & implement the European Health Authorities consultation strategy for a US-based client

BlueReg made recommendations to a US based client on which Health Authorities in the European...

Learn more

Support for a Paediatric Investigation Plan in the European Union, for a US-based client

Read our latest PIP case study following our recent webinar!   Discover how BlueReg provided...

Learn more

BlueReg continues to expand in the US opening its second North American office in Boston

Cambridge, Massachusetts, USA, December 13 2019, BlueReg, the consulting organization for life sciences companies, is...

Learn more